Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054140 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis, sponsored by Immunic.
- Active
- Registry status
- Phase 2
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT05054140 is a Phase 2 study of Multiple Sclerosis that is active but no longer recruiting, run by Immunic. The registered enrollment target is 450 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05054140, a Phase 2 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Immunic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
Conditions Studied
Interventions
- DRUG IMU-838
- DRUG Placebo matching IMU-838
Study Locations (20)
Other
- MHAT Pulse - Blagoevgrad
- MHAT"Heart and Brain" EAD - Burgas
- Dr. Maya Danovska - Pleven
- Dr. Plamen Bozhinov - Pleven
- UMHAT Pulmed - Plovdiv
- Dr. Rositsa Krasteva - Rousse
- Dr. Nikolay Georgiev - Shumen
- MHAT Shumen - Shumen
- Dr. Ivan Milanov - Sofia
- MHAT Lyulin - Sofia
- Dr. Rosen Ikonomov - Sofia
- Dr. Penko Shotekov - Sofia
Florida
- Dr. Sonia Kalirao - Coral Springs
- Collier Neurologic Specialists - Naples
- Prof. James Scott - Ormond Beach
Georgia
- Shepherd Center - Atlanta
Illinois
- Consultants in Neurology, Ltd. - Northbrook
Maryland
- Dr. Daniel Becker - Lutherville
Michigan
- Dr. Mirela Cerghet - Detroit
New Mexico
- University of New Mexico (UNM), MS Specialty Clinic - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05054140
The ClinicalTrials.gov registry entry for NCT05054140 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (23% lower). The listed sponsor is Immunic, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which IMU-838 is the first listed.
NCT05054140 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05054140 about?
NCT05054140 is a clinical study titled "Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis". Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER
What is the current status of trial NCT05054140?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2021-09-30. Estimated completion is 2025-01-07.
What conditions does trial NCT05054140 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT05054140?
The interventions under investigation include: IMU-838 (DRUG), Placebo matching IMU-838 (DRUG).
Who is sponsoring clinical trial NCT05054140?
This trial is sponsored by Immunic, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05054140 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.